Case Study: Viracta Therapeutics (NASDAQ:VIRX) and Harrow (NASDAQ:HROW)

Viracta Therapeutics ( NASDAQ:VIRX – Get Your Free Report ) and Harrow ( NASDAQ:HROW – Get Your Free Report ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

return

This table compares Viracta Therapeutics and Harrow’s net margins, return on equity and return on assets.

Volatility and risk

Viracta Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.75, indicating that its share price it is 25% less volatile than the S&P 500.

Institutional and privileged ownership

31.4% of Viracta Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 10.7% of Viracta Therapeutics shares are owned by insiders. Comparatively, 13.7% of Harrow shares are held by insiders. Strong institutional ownership is an indication that big money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Rating

This table compares Viracta Therapeutics and Harrow’s core revenue, earnings per share and valuation.

Harrow has higher revenue and earnings than Viracta Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst ratings

This is a summary of recent ratings and recommendations for Viracta Therapeutics and Harrow as provided by MarketBeat.

Viracta Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 2,344.44%. Harrow has a consensus target price of $56.67, suggesting a potential upside of 14.09%. Given Viracta Therapeutics’ higher possible upside, research analysts plainly believe Viracta Therapeutics is more favorable than Harrow.

Summary

Harrow beats Viracta Therapeutics on 9 of the 12 factors compared between the two stocks.

About Viracta Therapeutics

(Get a free report)

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-related cancers that affect patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug nanatinostat and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 trial for the treatment of multiple subtypes of Epstein-Barr virus-positive (EBV+) relapsed/refractory lymphoma, as well as a Open-label phase 1b/2 study for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product line also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

About Harrow

(Get a free report)

Harrow, Inc. operates as a healthcare company focused on ophthalmology. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 2006 and is headquartered in Nashville, Tennessee.

Get news and reviews for Viracta Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Viracta Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.